Abstract:Background. Pancreatic adenocarcinoma (PAAD) is among the most lethal diseases and has a dismal prognosis; however, efficient treatment is currently limited. Several studies have observed epigenetic variation during tumorigenesis, suggesting the potential role of RNA methylation, especially N6-methyladenosine (m6A) modification, as a novel epigenetic modification mediating PAAD prognosis. Methods. The expression levels of m6A-related genes were downloaded from The Cancer Genome Atlas-Pancreatic Adenocarcinoma (TCGA) and Genotype-Tissue Expression (GTEx) projects, and the findings were validated in four Expression Omnibus (GEO) datasets. A predictive model was constructed using a lasso regression and evaluated by a survival analysis and receiver operating characteristic curve. Consensus clustering identified two distinct subgroups with different immune activity signatures based on the expression pattern of m6A-related genes. The relationship between the mutation state of m6A-related genes and infiltration of immune cells was established and visualized using Tumor Immune Estimation Resource (https://cistrome.shinyapps.io/timer/). Results. Fourteen of twenty-one m6A-related genes were differentially expressed between PAAD and normal tissues in TCGA-GTEx cohort. Among these genes, HNRNPC, IGF2BP2 and YTHDF1 were further validated in four GEO datasets. Moreover, an m6A-based model exhibited moderate accuracy in predicting overall survival in PAAD samples. Additionally, potential m6A modification targets were screened by selecting genes from a set of 23,391 genes that not only harbored the most m6A-modified sites but also showed a robust correlation with PAAD survival. Moreover, we correlated the expression level of m6A-related genes with the immune microenvironment of pancreatic cancer for the first time. Specifically, both arm-level gain and deletion of ALKBH5 decreased the infiltration of CD8+T cells (P <0:05 and P <0:01, respectively). Conclusion. Collectively, our findings suggest a novel anticancer strategy for restoring balanced RNA methylation in tumor cells and guide clinical physicians in developing a new practical approach for considering the impact of related genes on prognosis.

N<SUP>6</SUP>-methyladenosine mRNA methylation of <i>PIK3CB</i> regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression

Abstract 4827: N6-Methyladenosine Modification of LINC00901 Promotes Pancreatic Cancer Progression

A Subset of Metastatic Pancreatic Ductal Adenocarcinomas Depends Quantitatively on Oncogenic Kras/Mek/Erk-Induced Hyperactive Mtor Signalling

Role of m6A modification in regulating the PI3K/AKT signaling pathway in cancer

Akt Methylation by SETDB1 Promotes Akt Kinase Activity and Oncogenic Functions

CircNEIL3 Regulatory Loop Promotes Pancreatic Ductal Adenocarcinoma Progression Via Mirna Sponging and A-to-I RNA-editing

N(6)-methyladenosine-mediated miR-380-3p maturation and upregulation promotes cancer aggressiveness in pancreatic cancer

N(6)-methyladenosine methylation-regulated polo-like kinase 1 cell cycle homeostasis as a potential target of radiotherapy in pancreatic adenocarcinoma

The N6-Methyladenosine- (M6a-) Associated Genes Act As Strong Key Biomarkers for the Prognosis of Pancreatic Adenocarcinoma

Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer

RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner

Research advances of N6‐methyladenosine in diagnosis and therapy of pancreatic cancer

The m7G Reader NCBP2 Promotes Pancreatic Cancer Progression by Upregulating MAPK/ERK Signaling

N6-methyladenosine regulates glycolysis of cancer cells through PDK4

m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer

The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma

Identification of Methyltransferase Modification Genes Associated with Prognosis and Immune Features of Pancreatic Adenocarcinoma.

N6 -methyladenosine–Mediated Upregulation of WTAPP1 Promotes WTAP Translation and Wnt Signaling to Facilitate Pancreatic Cancer Progression

S6K1-mediated Phosphorylation of PDK1 Impairs AKT Kinase Activity and Oncogenic Functions

MTA2-mediated inhibition of PTEN leads to pancreatic ductal adenocarcinoma carcinogenicity

The Gene RAD51AP1 Promotes the Progression of Pancreatic Cancer Via the PI3K/Akt/NF-κB Signaling Pathway.